SCOOP Trial: Community-Based Fracture Screening Reduces Hip Fractures by 28%

Published in The Lancet in 2018, the SCOOP trial (Screening in the Community to Reduce Fractures in Older Women) was the first large-scale randomized controlled trial to test whether a systematic, community-based fracture screening program could actually reduce fracture rates. The study enrolled 12,483 women aged 70 to 85 across 100 general practices in the United Kingdom. Women in the screening arm had their fracture risk calculated using the FRAX tool, followed by DXA scanning and treatment recommendations for those at high risk. The result: a 28% relative reduction in hip fractures compared to usual care.

The trial also showed that the screening program was cost-effective — in fact, cost-saving when factoring in the downstream expense of hip fracture treatment, hospitalization, and long-term care. This is critical evidence because it shifts the argument from "should we screen?" to "why are we not screening more systematically?"

Why This Matters for Midlife Health

Hip fractures in older adults carry devastating consequences: roughly one in five patients dies within a year, and many who survive never regain full independence. The SCOOP trial proved that these outcomes are preventable when at-risk individuals are identified and treated before the fracture happens. But the trial focused on women 70 and older. The implication for midlife health is clear — the trajectory that leads to a hip fracture at 75 begins with bone loss at 50. The earlier that trajectory is identified and tracked, the more options are available.

The Tracking Connection

SCOOP used FRAX as its screening gateway, but the tool requires clinical data: fracture history, family history, smoking status, BMI, and more. Kairos™ helps users maintain exactly this kind of organized health profile. When your risk factors, symptom patterns, and bone health data are documented longitudinally, you are not waiting for a screening program to find you. You are bringing the data that triggers the right clinical action at the right time.